
BLCO Stock Forecast & Price Target
BLCO Analyst Ratings
Bulls say
Bausch & Lomb is well-positioned for growth and profitability due to its restructuring efforts and strong management team. However, potential underperformance in contact lens sales could impact revenue projections. The company's product pipeline and focus on developing new medical devices and treatments should drive future growth, and positive results for existing medical assets have boosted investor confidence. With a solid portfolio and a favorable outlook in the eye care market, B&L has the potential to deliver strong returns for investors.
Bears say
Bausch & Lomb is facing headwinds in the form of weakening demand for its over-the-counter medications and increased competition in the contact lens market. Additionally, their flagship dry eye treatment, RESTASIS, has limitations in terms of delayed onset of action and potential side effects. Despite growth in the premium lens market, the company's overall growth may be hindered by these factors. The company's leadership has a strong background in the healthcare industry, but the return of former CEO Brent Saunders may signal a focus on corporate transactions over long-term growth. Investors should carefully consider these factors before investing in Bausch & Lomb's stock.
This aggregate rating is based on analysts' research of Bausch + Lomb Corp and is not a guaranteed prediction by Public.com or investment advice.
BLCO Analyst Forecast & Price Prediction
Start investing in BLCO
Order type
Buy in
Order amount
Est. shares
0 shares